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REPORT
Loss-of-Function Mutations in Euchromatin Histone Methyl
Transferase 1 (EHMT1) Cause the 9q34 Subtelomeric Deletion
Syndrome
Tjitske Kleefstra, Han G. Brunner, Jeanne Amiel, Astrid R. Oudakker, Willy M. Nillesen,
Alex Magee, David Genevie`ve, Vale´rie Cormier-Daire, Hilde van Esch, Jean-Pierre Fryns,
Ben C. J. Hamel, Erik A. Sistermans, Bert B. A. de Vries, and Hans van Bokhoven
A clinically recognizable 9q subtelomeric deletion syndrome has recently been established. Common features seen in
these patients are severe mental retardation, hypotonia, brachycephaly, flat face with hypertelorism, synophrys, ante-
verted nares, cupid bow or tented upper lip, everted lower lip, prognathism, macroglossia, conotruncal heart defects,
and behavioral problems. The minimal critical region responsible for this 9q subtelomeric deletion (9q5) syndrome has
been estimated to be !1 Mb and comprises the euchromatin histone methyl transferase 1 gene (EHMT1). Previous studies
suggested that haploinsufficiency for EHMT1 is causative for 9q subtelomeric deletion syndrome. We have performed a
comprehensive mutation analysis of the EHMT1 gene in 23 patients with clinical presentations reminiscent of 9q sub-
telomeric deletion syndrome. This analysis revealed three additional microdeletions that comprise the EHMT1 gene,
including one interstitial deletion that reduces the critical region for this syndrome. Most importantly, we identified two
de novo mutations—a nonsense mutation and a frameshift mutation—in the EHMT1 gene in patients with a typical
9q5 phenotype. These results establish that haploinsufficiency of EHMT1 is causative for 9q subtelomeric deletion
syndrome.
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Submicroscopic subtelomeric deletions of chromosome 9q
have been reported in 30 individuals, and this number
has been rapidly increasing since it was found recently
that such deletions are associated with a recognizable
mental retardation (MR) syndrome.1–8 Common features
in patients with 9q subtelomeric deletion syndrome are
severe MR, hypotonia, brachy(micro)cephaly, epileptic
seizures, flat face with hypertelorism, synophrys, ante-
verted nares, everted lower lip, carp mouth with macro-
glossia, and heart defects. The minimal critical region re-
sponsible for this 9q subtelomeric deletion phenotype
(9q) was originally estimated to be ∼1 Mb.1,4 This region
was subsequently reduced to an ∼700-kb region that con-
tains at least five genes—ZMYND19, ARRDC1, C9ORF37,
EHMT1, and CACNA1B—and several spliced ESTs8 (fig. 1).
In the latter study,8 a genotype-phenotype analysis was
performed with 15 individuals and their associated sizes
of 9q34.3 deletions. This study suggested that haploin-
sufficiency for one or more genes in the ∼700-kb critical
region is responsible for the common clinical findings of
9q34.3 subtelomeric deletion syndrome—craniofacialdys-
morphic features, hypotonia, obesity, microcephaly, and
speech anomalies, which were designated by the authors
as “CHOMS.” Other manifestations, such as cardiac de-
fects, seizures, limb and brain anomalies, recurrent respi-
ratory infections, hypothyroidism, and abnormal geni-
talia, were more common in individuals with larger de-
letions, which led to the hypothesis that these charac-
teristics were due to the deletion of one or more proxi-
mally located genes. However, in a recent study, we pos-
tulated that haploinsufficiency of the EHMT1 gene, which
encodes euchromatin histone methyltransferase 1 (Eu-
HMTase1 [MIM 607001]), was responsible for 9q syn-
drome.6 Characterization of the breakpoints in a female
with a balanced translocation t(X;9)(p11.23;q34.3) re-
vealed that the chromosome 9 breakpoint disrupted the
EHMT1 gene in intron 9. The patient presented typical
features of 9q subtelomeric deletion syndrome, including
severe MR, facial dysmorphisms, cardiac anomaly, sei-
zures, hearing loss, and behavioral problems. Thus, this
result suggested that subtelomeric 9q34.3 deletion syn-
drome is not a contiguous gene syndrome but that the
core phenotype of this recognizable entity is due to hap-
loinsufficiency of just one gene: EHMT1.
To find additional evidence for the causative role of the
EHMT1 gene, we performed mutation analysis in patients
with a clinical presentation reminiscent of 9q subtelo-
meric deletion syndrome. This analysis provides compel-
ling evidence for the causative role of the EHMT1 gene in
9q subtelomeric deletion syndrome.
Our study was performed on DNA from 23 patients with
MR with additional features seen in 9q syndrome. Min-
imal inclusion criteria were severe MR and suggestive cran-
iofacial dysmorphic features. However, most patients also
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Figure 1. Deletions of chromosome 9q34.3 identified in individuals with 9q subtelomeric deletion syndrome. The top bar is the genomic
organization of the relevant region in 9q34.3. The sizes and orientations of the known and predicted genes are indicated by gray
arrows. The sizes of the deletions reported elsewhere (L1–L3) and the new deletions identified in this study (P1–P3) are represented
by the bars. Gray lines are deleted regions, and the thick bars represent the regions with normal copy numbers. The intervening regions
are indicated by black lines. Deletions reported elsewhere are redrawn from Stewart et al.4 (L1), Harada et al.2 (L2), and Yatsenko et
al.8 (L3). A large deletion of at least 1 Mb, with the proximal border between the tMRPL41 gene and the TRAF2 gene, was identified
in patient P1. The deletion in P2 is similar to the critical region indicated by L3. P3 has a smaller interstitial deletion. The size of the
deletion was determined by FISH analysis and MLPA (lower panel). Unblackened boxes indicate probes located in exons or introns (i)
with reduced (∼50%) signal intensity, whereas the blackened boxes represent probes with normal intensities.
presented other features of 9q syndrome. All were pre-
viously screened for submicroscopic telomeric deletions,
by either FISH with routine telomeric probes or by mul-
tiplex ligation-dependent probe amplification (MLPA)
with routine probes.9 After we obtained informed consent,
genomic DNA was extracted from peripheral blood lym-
phocytes by a salt-extraction procedure.10
Initial MLPA analysis was performed using the standard
kits SALSA P019 or P036 Human Telomere Test Kit (MRC-
Holland), as described by Schouten et al.,11 with slight
modifications. Subsequent MLPA analyses were performed
with the recently developed P070 MRC-Holland kit con-
taining a probe matching exon 9 of the EHMT1 gene.
These MLPAs provided evidence for 9q subtelomeric de-
letions in three of the patients. These three patients had
a signal intensity of ∼50%. Patient 1 also had a decreased
signal for theMRPL41 probe and a normal signal atTRAF2,
which is indicative of a deletion exceeding the size of the
critical region defined elsewhere.8 However, patients 2 and
3 had a normal signal intensity for the MRPL41 probe,
suggesting the presence of a smaller deletion. To verify
these results and to fine-map the size of the deletions, we
developed additional MLPA probes within the critical in-
terval for 9q syndrome (fig. 1). Probe preparation has
been described elsewhere.9 The newly designed MLPA
probes covered exon 1 of ZMYND19, which is the most
distally located exon, and several exons or introns of both
EHMT1 and CACNA1B (table 1). Unfortunately, no suit-
able probes for ARRDC1 andC9ORF37 could be developed.
Results obtained with these additional MLPA probes con-
firmed the presence of a heterozygous deletion in all three
patients. Patients 2 and 3 had a decreased signal for all
probes in the EHMT1 gene. The proximal-flanking probe
in exon 1 of ZMYND19 was not deleted in either of these
two patients, which indicated that the maximum size of
the deletion is 670 kb. The deletion in patient 2 has a size
similar to the critical region defined by Yatsenko et al.8
and comprises ARRDC1, C9ORF37, EHMT1, CACNA1B,
and the ESTs represented by AK128414 and AK092558 and
by XM_932717, which encodes a protein that is highly
similar to isoform 2 of b-tubulin 8 (UNILIB and UCSC
Genome Browser). The deletion in patient 3 is even
smaller, since only exons 1–6 of CACNA1B were deleted.
Probes in exons 11, 15, 20, 25, and 30 of CACNA1B
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Table 1. Sequences of MLPA Probes
Genea
Primer (5′r3′)
Forward Reverse
ZMYND19_e1 GCCGTCGTTTTACACCCGGCCATGACCGACTTCAA ATTGGGTATCGTGCGGCTCGGCAGGAAACAGCTAT
EUHMT1_i6 CACCAGCGTCCTTCAGTTCTT TACCCAACAACCCTTGTTGCC
EUHMT1_e8 CCAGGAGACAGCACAGGGTACAT GGAAGTTTCTCTGGACTCCCTGG
EUHMT1_e9 CCAGATGTGCTGGAGACAGACGGCCTCCAGG AAGTGCCTCTCTGCAGCTGCCGGATGGAAAC
EUHMT1_e10 CCTCCAACAAGGCCCCGCTCCTCGTGC TGTGTGAAGACCACCGGGGCCGCATGG
EUHMT_e14 GTGTTTGTTCACAGTGGACGGAATTGACCCCAA CTTCAAAATGGAGCACCAGAATAAGCGCTCTCC
EUHMT1_i14 CGGTTCTTCCAGTGTAAGAGTTCCG TAGTGCTGTGAATCGGGCACAGAGT
EUHMT1_e16 CAGGACGCAGAGGGCTCTACGTGTT TGCACCTGGCTGCCAAGAAAGGCCA
EUHMT1_e18 GAGCTCTGGCTTGTGTCTGTT CAGGAGGAGAACATTTGCCTG
EUHMT1_e19 AACAAGGAAGGAGAGACGCCCCTGCAGTGGCGAGCCT CAACTCTCAGGTGTGGAGCGCTCTGCAGATGAGCAAGGCT
EUHMT1_e20 GACAGCGAGCCATGCCCCAGCAACTACAAGT ACGTCTCTCAGAACTGCGTGACGTCCCCCAT
EUHMT1_i22 GCCTGGGTTCACCACTACTCTCTAT GCCTCCCTTCACCACTACTCTCTAT
EUHMT1_e23 CTTTGTCTGCGAGTGAGTGAGTCCCTGGGTC ACCCCAAGCCTGGTGTCATTTCTGGGACGGA
EUHMT1_e24 GGTATGTTGGGGAGCTGATTTCAGACTCA GAAGCCGACGTTCGAGAGGAAGATTCTTA
EUHMT1_i25 GTTCTAAAAACTGCGACCTGGGATGCGGCACGG CAGATCGGGGTGAGGAAGCTTTGGCCTTGCCTT
EUHMT1_e26 CAGGTTTGACTATGGAGAGCGCT TCTGGGACATCAAAGGCAAGCTC
CACNA1B_e1 CAACCCCATCCCGGTCAAGCAGAACTGCT TCACCGTCAACCGCTCGCTCTTCGTCTTC
CACNA1B_e2 GCGTCTGCCGGCCAGTCCTTAACTCACGCACTCCATTCGAGTA TATGATCCTGGCCACCATCATCGCCAACTGCATCGTGCTGGCC
CACNA1B_e6 CCAGGACCCAACTTTGGCATCACCAACTTTGACAA TATCCTGTTTGCCATCTTGACGGTGTTCGAGTGCA
CACNA1B_e11 TCTAGATTGGATCTTGCTGGCGC GGGTTCCCTAAGGGTTGGA
CACNA1B_e15 GCCTTCCTGTTTTCCTCAGGTTCAACTTCCAGG ATGAGACTCCCACAACCAACTTCGACACCTTCC
CACNA1B_e20 CACACACTGCCCAGCACCTGTCTCCAGAAGGTGGAGGAA CAGCCAGAGGATGCAGACAATCAGCGGAACGTCACTCGC
CACNA1B_e25 CAATACCATCAAGTCTCTGAGAGTCCTTCGTGTCCTGCGGC CCCTCAAGACCATCAAACGGCTGCCCAAGCTCAAGGTTAGA
CACNA1B_e30 GGGGTGCTGGTACGTGCTTTGGTCCCTGCTTTGCCTTTTGACA ACCTATATTCTGGTTCCCCATCTGTAGGGCGACCTTTGGGGGC
a The number after the “e” or “i” corresponds to the exon or the intron, respectively, in which the probe is located.
Table 2. Changes Found with Direct
Sequencing of the EHMT1 Gene
DNA
Amino
Acid Exon
Pathogenic mutation:
c.1320_1332del13 p.P442fs 8
c.3409 CrT p.R1137X 24
Known polymorphisms:
c.351 TrC p.P117P 2
c.951 GrA p.S317S 5
c.996 TrC p.G332G 5
c.1275CrT p.L425L 7
New polymorphism:
c.1713GrA p.E571E 11
showed retained signal intensities, which indicated that
the distal border of the deletion was situated between ex-
ons 6 and 11 of the CACNA1B gene in patient 3. The
presence of the region extending from the 3′ exons of
CACNA1B toward the telomere was verified by FISH an-
alysis, with the use of the 9qter probe from Vysis, which
comprises D9S325, and probe RP1-112N3, which com-
prises D9S2168. Thus, patient 3 has a interstitial deletion
that is flanked by ZMYND19 (proximal) and exon 11 of
the CACNA1B gene (distal), encompassing 380 kb. This is
the smallest 9qter deletion identified so far and contains
ARRDC1, C9ORF37, EHMT1, AK128414, and the 5′ part of
the CACNA1B gene.
Since the EHMT1 gene was considered the most likely
candidate for 9q subtelomeric deletion syndrome, we
decided to sequence this gene in the remaining 20 pa-
tients in whom no deletion was identified. The GenBank
reference sequence for EHMT1 has accession number
NM_024757. The A of the ATG start codon in exon 2 is
defined as “position 1” for the numbering of mutations
and polymorphisms. Primers were designed to amplify all
26 exons and the three exons 15b, 27, and 28 of alternative
transcripts of the gene. Primer sequences and PCR con-
ditions are available on request. After purification with a
Qiagen PCR purification kit, the PCR samples were directly
sequenced on an Applied Biosystems 3730 automated se-
quencer, with the use of the same primers as in the PCR.
Mutation analysis identified seven sequence variants
(table 2). Three of these (c.351TrC, c.951GrA, and
c.996TrC) were known polymorphisms already listed in
SNP and EST databases. Another silent nucleotide transi-
tion, c.1275CrT (p.L425L), was found in 6 patients but
also in 17 of 85 ethnically matched control individuals
and was, therefore, considered to be a polymorphism. The
c.1713GrA (p.E571E) was not reported elsewhere, but, ac-
cording to several splice-site prediction programs (ESE
Finder), it is unlikely to have a pathogenic effect. Unfor-
tunately, we were not able to test the parents of the patient
for this sequence change. Two nucleotide changes ap-
peared to be causative mutations, because they disrupt the
ORF of the EHMT1 gene (fig. 2). A nonsense mutation,
c.3409CrT, in exon 24 was identified in patient 4 and
predicts a premature stop codon (p.R1137X). In patient 5,
we identified a 13-bp deletion (1320_1332del13) in exon
8 that causes a frameshift and a premature stop that pre-
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Figure 2. Mutations in the EHMT1 gene identified in P4 and P5. A, De novo nonsense mutation identified in exon 24 of P4, which
predicts premature stop codon R1137X. B, Deletion of 13 bp identified in exon 8 of P5. The deletion is indicated by the box. The
endpoints of the deletion carry the same AGAC tetranucleotide sequence (underlined), which suggests that it has arisen as a result of
a replication error. Top chromatogram is the sequence from a control individual; P5-S and P5-AS are the sense and antisense (reverse-
complement) sequences from patient 5. C, Agarose gel showing that the 13-bp deletion has also occurred de novo. Sizes of the PCR
products on the agarose gel: 324-bp normal exon 8 PCR product and 311-bp mutant product. Lane C is a control sample. D, Gene
structure of the EHMT1 gene and protein domain structure of the three predicted isoforms that result from alternative splicing. Isoform
1 is the canonical Eu-HMTase1 protein, which has eight ankyrin repeats, a pre-SET domain, and a SET domain. Isoform 2 lacks most of
these recognizable C-terminal protein domains because of the use of an alternative exon 15. Isoform 3 is produced by the use of two
alternative last exons. As a consequence, this isoform has an incomplete SET domain.
dicts a mutant protein of 526 aa. The two EHMT1 gene
mutations are predicted to give rise to reduced levels of
functional protein because of nonsense-mediated decay
of the mutant transcripts.12 If such transcripts were trans-
lated, then the mutant protein would have C-terminal
truncations that lack functional SET domains (fig. 2D).
The p.R1137X mutation is predicted to affect the major
isoform 1 and isoform 3 but not isoform 2 of the Eu-
HMTase1 protein (fig. 2D).
Segregation studies performed for both mutations re-
vealed that the changes were not present in the pheno-
typically normal parents. We confirmed paternity by hap-
lotyping 15 informative markers throughout the genome,
using the AmpFlSTR Profiler Plus PCR Amplification Kit
(Applied Biosystems) and following the manufacturer’s
protocol. Thus, both mutations represent de novo changes,
which provides compelling evidence for their causative
role.
Table 3 shows a summary of the clinical characteristics
of the five patients presented in this report. Detailed clin-
ical information is provided in appendix A (online only).
In general, no major clinical differences could be observed
between these 5 and the remaining 18 patients. The fea-
tures of the three patients with the deletion and the two
patients with the mutations that create a premature stop
codon are compared with the features commonly reported
in patients with a submicroscopic subtelomeric 9q dele-
tion. All patients had typical facial dysmorphisms, in-
cluding flat face with hypertelorism, eyebrow abnormal-
ities, midfacial hypoplasia, anteverted nares, cupid bow
of upper lip, and everted lower lip (fig. 3). Also, other
features of the patients with the EHMT1 mutations were
reminiscent of 9q deletion syndrome, such as severe MR,
seizures, and congenital heart defect. There is not an ob-
vious disparity between the three patients with the dele-
tion and the two patients with the intragenic mutation.
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Table 3. Clinical Features of the Five Presented Patients Compared with the
Phenotypic Characteristics of 9q Subtelomeric Deletion Syndrome
Features of 9q Syndrome
Submicroscopic
(%)Np 30
This study
Deletion
EHMT1
Mutation
P1 P2 P3 P4 P 5
General:
Age (years) … 8 1.5 36 4 16
MR 28/28 (100) Severe Severe Severe Severe Severe
Obesity 5 (16)     
Facial features:
Microcephaly 25 (83)     
Brachycephaly 12 (33)     
Flat face 5 (16)     
Midface hypoplasia 16 (53)     
Coarse facies 8 (27)     
Hypertelorism 15 (50)     
Synophrys 16 (53)     
Downslant palpebral fissures 6 (20)     
Upslant palpebral fissures 5 (16)     
Arched eyebrows 8 (27)     
Short nose 17 (57)     
Anteverted nostrils 12 (33)     
Carp mouth/tented lip 23 (77)     
Macroglossia/tongue protrusion 12 (33)     
Natal teeth 1 (3)     
Thick/everted lower lip 5 (16)     
Pointed chin/prognathism 5 (16)     
Malformed ears 12 (33)     
Other features:
Brachydactyly 5 (16)     
Simian crease 10 (30)     
Abnormal genitals (males) 10 (33)     
Cardiac anomaly 15 (50)     
Anal atresia 2 (7)     
Alopecia 3 (10)     
Depigmentation 1 (3)     
Renal cysts 2 (7)     
Hydronephrosis 2 (7)     
Behavioral problems 4 (9)     
Sleep disturbances 3 (10)     
Hearing loss 6 (20)     
Hypotonia 15 (50)     
Seizures 10 (30)     
They each have the characteristic facial features and severe
MR. On the basis of the clinical studies of these five pa-
tients, some additional features should be included in the
list of characteristic features of this syndrome. The eye-
brows of several patients seem straight and situated lower
than usual. The designation “carp mouth” is not always
justified, since the upper lip appears quite tented or shows
a prominent cupid bow. Remarkably, depigmented skin
patches were observed in three patients with mutations
but have been reported elsewhere in only one patient.4
These observations clearly underscore the fact that the
prominent features of 9q deletion syndrome are caused
by haploinsufficiency of a single gene rather than by a
contiguous gene deletion.
It has been suggested elsewhere that specific clinical en-
dophenotypes correlate with the extent of 9q34.3 dele-
tion.8 This correlation may be true for some rare features,
such as trigonocephaly, which has been observed in an
individual with a large deletion extending proximally
from the TRAF2 gene. However, the present data clearly
demonstrate that 9q syndrome is a single-gene syn-
drome, not a contiguous–gene deletion syndrome. We
were unable to detect any association of the extent of the
deletion or of the type of mutation with specific pheno-
types. For example, conotruncal heart defects and seizures
are present in many patients with a 9q telomeric deletion
but were also observed in patient 4, who carries the
p.R1137X nonsense mutation. The two patients with mu-
tations are as severely affected as the three patients with
deletions, and the patients with a regular 9qter deletion
are as severely affected as those described in the literature.
Therefore, our data do not support the use of the acronym
“CHOMS” for those patients with a deletion comprising
only EHMT1 and CACNA1B.8
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Figure 3. A, Patient 1 at age 8 years. B, Patient 2 at age 1 year and 6 mo. C, Patient 3 at different ages: neonate (top left), 11
years (top right), and 36 years (bottom panels). D, Patient 4 at different ages: 6 mo (top left), 18 mo (top right), and 4 years (bottom
panels). E, Patient 5 at age 16 years. Note the characteristic facial dysmorphisms in all the patients. Written consent to publish these
photographs was obtained from the parents of each patient.
The patients in the present study were carefully selected
on the basis of the reported clinical characteristics of 9q
syndrome. This selection led to the identification of caus-
ative mutations in 5 (22%) of 23 patients, three submi-
croscopic deletions, and two small mutations in the
EHMT1 gene. These data emphasize the importance of
careful clinical analysis before mutation analysis. Because
of the hypotonia, brachycephaly, midface hypoplasia, up-
ward slant of the eyes, and macroglossia, 9q syndrome
may be difficult to differentiate from Down syndrome
(MIM 190685), especially at birth. Furthermore, because
of the facial coarseness, sleep disorders, obsessive-com-
pulsive disorders, stereotypic movements, bursts of anger,
and autohetero aggressivity, 9q syndrome has many over-
lapping features with the Smith-Magenis syndrome (SMS
[MIM 182290]). This overlap can be concluded also from
a study on a large cohort of subtelomeric FISH studies in
which, of 11 patients with a 9qter deletion, 2 patients had
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a clinical diagnosis of SMS and one had a clinical diagnosis
of Down syndrome.13 Our data also indicate that 9q sub-
telomeric deletion syndrome may be a relatively common
clinical entity. This finding is in line with the notion that
9q34 subtelomeric deletions comprised ∼6% (11 of 175)
of all subtelomeric deletions.13
Histone methylation plays an important role in mod-
ulating chromatin structure and function.14,15 Histone
methylation occurs on arginine and lysine residues at the
N-terminal tails of histones H3 and H4. Thus far, six lysine
residues located on histones H3 (lysines 4, 9, 27, 36, and
79) and H4 (lysine 20) have been reported to be sites of
methylation. Lysine 9 methylation (H3-K9) is the best
studied because of its fundamental role in heterochro-
matin formation, transcriptional silencing, X-chromo-
some inactivation, and DNA methylation.16
Eu-HMTase1 was identified in 200217 and was found to
be closely related to the enzyme G9a. These enzymes ap-
peared to be H3-K9 HMTases, present in euchromatic re-
gions that formed complexes with heterochromatin pro-
tein 1 (HP1a and HP1g), E2F-6, and Polycomb group (PcG)
proteins.17,18 It is of note that the X-linked nuclear protein,
which is mutated in the a-thalassemia MR syndrome
(ATRX [MIM 301040]) and in several other syndromic and
nonsyndromic X-linked MR (XLMR) conditions,19 also in-
teracts with HP1 and with the SET domain of the PcG
protein EZH2.20 Interestingly, the ATRX and related syn-
dromes share several features with 9q syndrome, such as
severe MR, midface hypoplasia, microcephaly, cardiovas-
cular defects, and seizures. Other genes for syndromic and
nonsyndromic XLMR have been implicated in chromatin
condensation as well. The methyl-CpG-binding protein 2
(MECP2) protein, which underlies Rett syndrome (MIM
312750) and nonsyndromic XLMR, is a methyl-CpG-bind-
ing protein that recruits repressor complexes and indi-
rectly causes chromatin condensation through recruit-
ment of histone deacetylases.21 Likewise, Kruppel-asso-
ciated box (KRAB) zinc-finger proteins are found in re-
pressor complexes in euchromatic DNA, together with
HP1 and another H3K9 methyltransferase, SETDB1.22 Mu-
tations in three highly related KRAB-domain zinc-finger
genes are associated with XLMR.23–25 It thus seems that
gene silencing mediated by histone modifications are cru-
cial for proper neuronal function and development.18
Recently, knockout mice have been generated for the
G9a and EHMT1 genes, which are also known as “G9a-
related methyltransferase” and “GLP,” respectively.26,27
The phenotypes observed from germline mutations of the
G9a and EHMT1 genes were identical in many respects,
including embryonic lethality, drastic reduction of H3-K9
mono- and dimethylation, induction of MAGEA genes,
and HP1 relocalization. These and other results indicated
that G9a and Eu-HMTase1 function cooperatively, prob-
ably in the same complexes, to mediate H3-K9 methyla-
tion at euchromatin. Interestingly, G9a-null embryo stem
cells show altered DNA methylation in the Prader-Willi
imprinted region, indicating that one or more neuronal
target genes are located in that region.28 Strikingly, it was
reported that no significant differences were observed be-
tween Glp/ and Glp/ mice and that heterozygous mice
were born in Mendelian ratios. This would suggest that
EHMT1 haploinsufficiency in mice has less dramatic ef-
fects than it does in humans, although it is possible that
behavioral and cognitive defects have gone unnoticed in
heterozygous mice.
The findings here confirm our previous hypothesis that
haploinsufficiency of the gene EHMT1 is the cause of 9q
syndrome. Although we may have missed mutations in
regulatory regions of the gene, it seems likely that mu-
tations in other genes give rise to a similar phenotype.
Likely candidate genes are those that encode components
of the same histone methyltransferase complex, such as
EHMT2 encoding G9a or target genes whose expression is
repressed by the chromatin remodeling activity of this
complex. Functional studies are needed to give more in-
sight into the exact pathways through which Eu-HMTase1
exerts its effects.
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.nih.gov/
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim (for Eu-HMTase1, Down syndrome, SMS,
ATRX, and Rett syndrome)
UCSC Genome Browser (Golden Path), http://genome.cse.ucsc
.edu/ (May 2004 Build)
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